Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy

被引:25
作者
Chen, B
Timiryasova, TM
Gridley, DS
Andres, ML
Dutta-Roy, R
Fodor, I
机构
[1] Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Loma Linda, CA 92350 USA
[2] Loma Linda Univ, Sch Med, Dept Microbiol & Mol Genet, Loma Linda, CA 92350 USA
[3] Loma Linda Univ, Sch Med, Dept Radiat Med, Loma Linda, CA 92350 USA
关键词
glioma; IL-2; IL-12; toxicity; vaccinia virus;
D O I
10.1006/cyto.2001.0906
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Single intratumoural treatment of nude mice with a vaccinia virus (VV)-expressing interleukin-1 (IL-2) or IL-12 induced significant tumour growth inhibition associated with clear signs of toxicity. At a low virus dose, only some treated animals showed signs of toxicity. We characterized and compared the activity of NK and B cells and major pro-inflammatory factors (IFN-gamma, TNF-alpha) in treated animals with and without toxicity. One week after treatment animals exhibiting signs of cytokine-related toxicity showed dramatic increases in several measured parameters. High leukocyte and lymphocyte counts in blood and marked increases in NK and CD25(+) cells in both blood and spleen were associated with IL-2-induced toxicity, while IL-12-induced toxicity was related to a great elevation of CD25(+) cells in blood and CD71(+) cells in the spleen. In contrast, immune activation in animals free of toxicity was observed on day 2 after the treatment, which drastically declined by day 7. Thus, immune responses induced by IL-2 and IL-12 therapy appear to play important roles in both tumour inhibition and the accompanying toxicity. Short-term effects induced by IL-2 and IL-12 could be critical for antitumour therapy that prolongs survival and protects from adverse side effects.
引用
收藏
页码:305 / 314
页数:10
相关论文
共 39 条
[21]  
Leonard JP, 1997, BLOOD, V90, P2541
[22]  
MEKO JB, 1995, CANCER RES, V55, P4765
[23]   Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-Inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy [J].
Narvaiza, I ;
Mazzolini, G ;
Barajas, M ;
Duarte, M ;
Zaratiegui, M ;
Qian, C ;
Melero, I ;
Prieto, J .
JOURNAL OF IMMUNOLOGY, 2000, 164 (06) :3112-3122
[24]   Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model [J].
Nasu, Y ;
Bangma, CH ;
Hull, GW ;
Lee, HM ;
Wang, J ;
McCurdy, MA ;
Shimura, S ;
Yang, G ;
Timme, TL ;
Thompson, TC .
GENE THERAPY, 1999, 6 (03) :338-349
[25]   MECHANISM OF INTERLEUKIN 12-MEDIATED TOXICITIES DURING EXPERIMENTAL VIRAL-INFECTIONS - ROLE OF TUMOR-NECROSIS-FACTOR AND GLUCOCORTICOIDS [J].
ORANGE, JS ;
SALAZARMATHER, TP ;
OPAL, SM ;
SPENCER, RL ;
MILLER, AH ;
MCEWEN, BS ;
BIRON, CA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (03) :901-914
[26]   IN-VIVO GENE-THERAPY OF A MURINE PANCREAS TUMOR WITH RECOMBINANT VACCINIA VIRUS ENCODING HUMAN INTERLEUKIN-1BETA [J].
PEPLINSKI, GR ;
TSUNG, K ;
MEKO, JB ;
NORTON, JA .
SURGERY, 1995, 118 (02) :185-191
[27]  
Pham-Nguyen KB, 1999, INT J CANCER, V81, P813, DOI 10.1002/(SICI)1097-0215(19990531)81:5<813::AID-IJC24>3.0.CO
[28]  
2-I
[29]  
Schneeberger A, 1999, J IMMUNOL, V162, P6650
[30]  
Shah MH, 2000, CANCER J SCI AM, V6, pS45